The course of galactose elimination capa
โ
C Merkel; G Marchesini; A Fabbri; S Bianco; G Bianchi; E Enzo; D Sacerdoti; M Zo
๐
Article
๐
1996
๐
John Wiley and Sons
๐
English
โ 183 KB
๐ 2 views
## ditions and in response to other treatments. (HEPATOL- There is increasing interest for the use of surrogate OGY 1996;24:820-823.) end points in the evaluation of treatments in patients with liver disease, but adequate validation is seldom Recent research in clinical epidemiology focused on th